Systematic review—Time to malignant transformation in low-grade gliomas: Predicting a catastrophic event with clinical, neuroimaging, and molecular markers

Satar, Zabina; Hotton, Gary; Samandouras, George

doi:10.1093/noajnl/vdab101

Cited by 8 publications

(24 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was found that the mechanism of epilepsy induced by glioma may be that the invasive tumor cells change the excitability of the surrounding normal neurons, making them the pacemakers of seizures. However, the destructive effect of malignant tumors on peripheral neurons and their axons obstructs the occurrence and transmission of epilepsy [ 26 , 27 ]. In addition, patients with tumor over 5 cm accounted for 27.45% in the control group and 52.63% in the observation group, which was larger in the observation group than that in the control group.…”

Section: Discussionmentioning

confidence: 99%

Analysis of Clinical Characteristics and Risk Factors of Postoperative Recurrence and Malignant Transformation of Low-Grade Glioma

Luo

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

This research was developed to explore the clinical characteristics and related risk factors of postoperative recurrence and malignant transformation of low-grade glioma (LGG). The subjects were rolled into observation group (19 cases) and control group (51 cases) according to recurrence and malignant transformation during the follow-up period. The clinical data of the two groups were compared, and the risk factors of recurrence and malignant transformation were analyzed with the time of recurrence and malignant transformation as independent variables. The experimental results showed that the proportion of patients aged over 45 years in the observation group (63.16%) was higher than that in the control group (50.98%). The proportion of preoperative functional status score (KPS) ≥80 in the observation group (68.42%) was lower than that in the control group (78.43%). The proportion of patients with tumor over 5 cm in the control group (27.45%) was lower than that in the observation group (52.63%), and the proportion of total resection of tumor in the control group (47.06%) was higher than that in the observation group (21.05%). Furthermore, the multivariate analysis showed that preoperative KPS score, preoperative duration of disease, resection scope, postoperative treatment, oncotesticular antigen (OY-TES-1) mRNA, P53, mouse double microbody amplification gene (MDM2), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor (EGFR) were independent risk factors (all P < 0.05 ). In summary, patients with postoperative recurrence and malignant transformation had poorer physical condition and higher degree of malignancy before surgery. Preoperative KPS score, duration of disease, surgical resection scope, postoperative treatment, OY-TES-1 mRNA, P53, MDM2, VEGF, and EGFR were the risk factors.

show abstract

Section: Discussionmentioning

confidence: 99%

Analysis of Clinical Characteristics and Risk Factors of Postoperative Recurrence and Malignant Transformation of Low-Grade Glioma

Luo

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…GBM tumors are known to either develop de novo or from LGG tumors. In fact, without treatment, LGGs almost always develop into high grade gliomas (Satar et al, 2021). Recent classification of metabolic properties of LGG tumors has been used to identify important genes in the progression of GBM from LGG, including alterations in lipid metabolism (Wu et al, 2019) and glutamate-and calcium-signaling (Pei et al, 2020).…”

Section: Introductionmentioning

confidence: 99%

High Expression of Glycolytic Genes in Clinical Glioblastoma Patients Correlates With Lower Survival

Stanke

Wilson

Kidambi

2021

Front. Mol. Biosci.

View full text Add to dashboard Cite

Glioblastoma (GBM), the most aggressive brain tumor, is associated with a median survival at diagnosis of 16–20 months and limited treatment options. The key hallmark of GBM is altered tumor metabolism and marked increase in the rate of glycolysis. Aerobic glycolysis along with elevated glucose consumption and lactate production supports rapid cell proliferation and GBM growth. In this study, we examined the gene expression profile of metabolic targets in GBM samples from patients with lower grade glioma (LGG) and GBM. We found that gene expression of glycolytic enzymes is up-regulated in GBM samples and significantly associated with an elevated risk for developing GBM. Our findings of clinical outcomes showed that GBM patients with high expression of HK2 and PKM2 in the glycolysis related genes and low expression of genes involved in mitochondrial metabolism-SDHB and COX5A related to tricarboxylic acid (TCA) cycle and oxidative phosphorylation (OXPHOS), respectively, was associated with poor patient overall survival. Surprisingly, expression levels of genes involved in mitochondrial oxidative metabolism are markedly increased in GBM compared to LGG but was lower compared to normal brain. The fact that in GBM the expression levels of TCA cycle and OXPHOS-related genes are higher than those in LGG patients suggests the metabolic shift in GBM cells when progressing from LGG to GBM. These results are an important step forward in our understanding of the role of metabolic reprogramming in glioma as drivers of the tumor and could be potential prognostic targets in GBM therapies.

show abstract

“…The rate of malignant transformation of LGG ranges from 25% to 72% [ 46 ] and it is influenced by several risk factors, such as preoperative tumor size, velocity of diametric expansion, astrocytoma histology, extent of resection, and treatment with chemotherapy, radiotherapy, and adjuvant chemo-radiotherapy [ 46 ].…”

Section: Discussionmentioning

confidence: 99%

Brain Gliomas and Ollier Disease: Molecular Findings as Predictive Risk Factors?

Corvino

Mariniello

Corazzelli

et al. 2022

Cancers

View full text Add to dashboard Cite

Background: Ollier disease (OD) is a rare nonhereditary type of dyschondroplasia characterized by multiple enchondromas, with typical onset in the first decade of life. Surgery is the only curative treatment for primary disease and its complications. Patients with OD are at risk of malignant transformation of enchondromas and of occurrence of other neoplasms. Methods: A wide literature review disclosed thirty cases of glioma associated with OD, most of them belonging to the pre-molecular era. Our own case was also included. Demographic, clinical, pathologic, molecular, management, and outcome data were analyzed and compared to those of sporadic gliomas. Results: Gliomas associated with OD more frequently occur at younger age, present higher rates of multicentric lesions (49%), brainstem localizations (29%), and significantly lower rates of glioblastomas (7%) histotype. The IDH1 R132H mutation was detected in 80% of gliomas of OD patients and simultaneously in enchondromas and gliomas in 100% of cases. Conclusions: The molecular data suggest a higher risk of occurrence of glioma in patients with enchondromas harboring the IDH1 R132H mutation than those with the IDH1 R132C mutation. Thus, we suggest considering the IDH1 R132H mutation in enchondromas of patients with OD as a predictive risk factor of occurrence of glioma.

show abstract

Systematic review—Time to malignant transformation in low-grade gliomas: Predicting a catastrophic event with clinical, neuroimaging, and molecular markers

Cited by 8 publications

References 75 publications

Analysis of Clinical Characteristics and Risk Factors of Postoperative Recurrence and Malignant Transformation of Low-Grade Glioma

Analysis of Clinical Characteristics and Risk Factors of Postoperative Recurrence and Malignant Transformation of Low-Grade Glioma

High Expression of Glycolytic Genes in Clinical Glioblastoma Patients Correlates With Lower Survival

Brain Gliomas and Ollier Disease: Molecular Findings as Predictive Risk Factors?

Contact Info

Product

Resources

About